Ronald Hoffman Selected Research

Splenomegaly

7/2022	JAK inhibitors in the treatment of myelofibrosis.
7/2020	Modern management of splenomegaly in patients with myelofibrosis.
1/2018	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
1/2018	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
1/2017	A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
1/2017	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
12/2016	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis.
7/2015	CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
11/2014	JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.
7/2013	Clarifying the use of ruxolitinib in patients with myelofibrosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ronald Hoffman Research Topics

Disease

59	Primary Myelofibrosis (Myelosclerosis) 07/2022 - 05/2005
32	Polycythemia Vera 12/2022 - 08/2007
31	Neoplasms (Cancer) 10/2022 - 08/2007
16	Splenomegaly 07/2022 - 04/2008
12	Essential Thrombocythemia 12/2022 - 07/2011
7	Blast Crisis (Blast Phase) 01/2022 - 03/2011
6	Myeloproliferative Disorders (Myeloproliferative Disorder) 10/2019 - 08/2005
6	Anemia 01/2018 - 10/2005
5	Fibrosis (Cirrhosis) 01/2022 - 01/2016
5	Thrombocytopenia (Thrombopenia) 01/2018 - 07/2007
4	Thrombocytosis (Thrombocythemia) 01/2022 - 08/2007
3	Cytopenia 07/2022 - 01/2011
3	Thalassemia 01/2021 - 12/2003
3	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 05/2011
2	Disease Progression 01/2022 - 01/2021
2	Thrombosis (Thrombus) 01/2022 - 11/2015
2	Hypoxia (Hypoxemia) 11/2019 - 10/2018
2	Hyperplasia 10/2018 - 08/2007
2	Chromosome Aberrations (Chromosome Abnormalities) 11/2014 - 07/2007
2	Sickle Cell Anemia (Hemoglobin S Disease) 05/2004 - 12/2003
1	von Willebrand Diseases (von Willebrand's Disease) 01/2022
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2021
1	Residual Neoplasm 11/2020
1	Infections 01/2020
1	Liver Cirrhosis (Hepatic Cirrhosis) 11/2019
1	Inflammation (Inflammations) 10/2018
1	Hemorrhage 10/2018
1	Iron Deficiencies 10/2018
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2018
1	Leukemia 01/2016

Drug/Important Bio-Agent (IBA)

18	ruxolitinibIBA 10/2021 - 06/2012
7	InterferonsIBA 12/2022 - 11/2010
7	Pharmaceutical PreparationsIBA 07/2022 - 02/2011
6	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2022 - 02/2011
6	Janus Kinase InhibitorsIBA 07/2022 - 08/2012
6	CytokinesIBA 01/2022 - 07/2007
5	Proteins (Proteins, Gene)FDA Link 10/2022 - 08/2011
5	Phosphotransferases (Kinase)IBA 10/2021 - 10/2013
5	Janus Kinase 2IBA 01/2018 - 08/2007
5	ChromatinIBA 08/2011 - 07/2007
4	Decitabine FDA Link 01/2021 - 12/2003
3	CollagenIBA 01/2022 - 01/2016
3	imetelstatIBA 10/2021 - 01/2018
3	Histone Deacetylase InhibitorsIBA 01/2017 - 07/2012
3	PanobinostatIBA 01/2017 - 07/2012
3	Biological ProductsIBA 01/2016 - 08/2007
2	peginterferon alfa-2a (Pegasys)FDA Link 01/2022 - 10/2019
2	Reticulin (Reticular Fiber)IBA 01/2022 - 01/2016
2	anagrelide (Agrylin)FDA LinkGeneric 01/2022 - 06/2015
2	Telomerase (Telomerase Reverse Transcriptase)IBA 10/2021 - 01/2018
2	RG7388IBA 11/2020 - 01/2019
2	Janus KinasesIBA 11/2019 - 11/2014
2	lestaurtinibIBA 01/2019 - 01/2015
2	Hemoglobins (Hemoglobin)IBA 01/2018 - 02/2013
2	Janus Kinase 1IBA 01/2018 - 01/2017
2	Antidepressive Agents (Antidepressants)IBA 01/2017 - 01/2017
2	Thrombopoietin (c-mpl Ligand)IBA 01/2016 - 08/2007
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2016 - 02/2014
2	AZD 1480IBA 02/2015 - 11/2014
2	RG7112IBA 07/2014 - 02/2014
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2012 - 02/2011
2	Erythropoietin FDA Link 04/2012 - 10/2005
2	AndrogensIBA 02/2011 - 10/2005
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2007 - 08/2007
1	Interleukin-8A Receptors (Receptors, Interleukin 8A)IBA 01/2022
1	Syntex adjuvant formulationIBA 01/2022
1	reparixinIBA 01/2022
1	dimemorfan (AT 17)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	Transferrin (beta 2 Transferrin)IBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	GATA1 Transcription FactorIBA 01/2021
1	Extracellular Matrix ProteinsIBA 11/2019
1	CholesterolIBA 11/2019
1	CalreticulinIBA 01/2019
1	Immune Checkpoint InhibitorsIBA 01/2019
1	HepcidinsIBA 10/2018
1	IronIBA 10/2018
1	Ferritins (Ferritin)IBA 10/2018
1	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2018
1	INCB039110IBA 01/2017
1	EnzymesIBA 01/2017
1	4- (5- benzo(1,3)dioxol- 5- yl- 4- pyridin- 2- yl- 1H- imidazol- 2- yl)benzamideIBA 12/2016
1	Transforming Growth Factor beta (TGF-beta)IBA 12/2016
1	Thrombopoietin ReceptorsIBA 01/2016
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 01/2016
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2015
1	Lipocalin-2IBA 08/2015
1	LipocalinsIBA 08/2015
1	CHZ868IBA 07/2015

Therapy/Procedure

42	Therapeutics 12/2022 - 09/2006
7	Transplantation 01/2020 - 07/2006
6	Stem Cell Transplantation 11/2018 - 01/2007
5	Hematopoietic Stem Cell Transplantation 01/2021 - 05/2005
3	Splenectomy 01/2016 - 04/2008
2	Cell Transplantation 01/2019 - 08/2012
2	Lasers (Laser) 01/2011 - 05/2009
1	Induction Chemotherapy 01/2022
1	Duration of Therapy 11/2020
1	Precision Medicine 11/2018